Ticker Details
Kyverna Therapeutics, Inc. Common Stock
IPO Date:	February 9, 2024
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$596.4M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.38 | 4.83%
Avg Daily Range (30 D):	$0.24 | 2.80%
Avg Daily Range (90 D):	$0.34 | 3.73%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	.83M
Avg Daily Volume (90 D):	.85M

Trade Size
Avg Trade Size (Sh.):	93
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	73

Institutional Trades
Total Institutional Trades:	179
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$2.92M
Avg Institutional Trade (90 D):	$2.04M
Avg Institutional Trade Volume:	.18M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.49M
Avg Closing Trade (30 D):	$3.9M
Avg Closing Trade (90 D):	$2.66M
Avg Closing Volume:	264.21K

News

Jun 10, 2026 @ 5:00 PM Lupus Nephritis Clinical Trial Landscape Becomes I... Source: Delveinsight

Jun 8, 2026 @ 6:34 PM Kyverna Therapeutics vs. Vertex Pharmaceuticals: W... Source: Brendan Coffey

May 14, 2026 @ 12:00 PM Kyverna Therapeutics to Present at Upcoming Invest... Source: Na

Apr 21, 2026 @ 10:45 PM Kyverna Presents Registrational Trial Primary Anal... Source: Na

Feb 24, 2026 @ 1:00 PM Kyverna Therapeutics Appoints Biotech Leaders Srav... Source: Na

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-3.27	$-.66	$-.79
Diluted EPS	$-3.27	$-.66	$-.79
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-156.4M	$-39.73M	$-37.8M
Operating Income / Loss	$-163.79M	$-41.37M	$-39.28M
Cost of Revenue
Net Cash Flow	$-24.68M	$-91.9M	$89.93M
PE Ratio